Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
July 06 2020 - 8:30AM
Business Wire
— Proven Biopharmaceutical Leader Brings Deep,
Global Experience with Technical Development, Manufacturing and
Supply Chain Operations —
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical
company developing and commercializing treatments for potentially
life-threatening food allergies, today announced the appointment of
Narinder Singh as Executive Vice President, Technical Operations.
Mr. Singh is a proven biopharmaceutical executive with over two
decades of deep technical, operational, and strategic leadership
experience in end-to-end biopharmaceutical clinical development and
commercialization, launch, and life cycle management for a variety
of biopharmaceuticals such as biologics, biosimilars, complex
generics, peptide vaccines and T-cell therapies.
“I am delighted to welcome Narinder, whose deep technical
development, manufacturing and supply chain operations experience
will be invaluable as we continue to support the launch of
PALFORZIA® in the U.S and the potential launch of PALFORZIA in
Europe next year,” said Jayson Dallas, M.D., President and CEO of
Aimmune Therapeutics. “His appointment further strengthens our
Leadership Team as we continue to build our global commercial
footprint. Moreover, his experience across a variety of
biopharmaceuticals is highly relevant as we advance our pipeline,
including our monoclonal antibody AIMab7195.”
Prior to joining Aimmune, Mr. Singh was Senior Vice President,
Pharmaceutical Sciences and Manufacturing at Genocea Biosciences
where he was instrumental in technical development and building
manufacturing supply chain operations for a personalized
neoantigen-based vaccine and T-cell therapy for solid cancers.
Prior to Genocea, Narinder served at Momenta Pharmaceuticals and at
Amgen Inc. for 18 years in a variety of leadership roles in drug
product and combination device development, commercialization, and
manufacturing operations. Narinder holds a B.Tech/M.Tech in
Biochemical Engineering and Biotechnology from the Indian Institute
of Technology in Delhi, India; an M.S. in Chemical Engineering from
the University of Houston, and; an M.B.A. from the UCLA Anderson
School of Management.
“I am thrilled to join the leadership team at Aimmune and to be
part of advancing the company’s mission. I look forward to the
opportunity to be part of the development of first-in-class
medicines that have the potential to change the lives of children
and families living with life-threatening food allergies,” said Mr.
Singh.
About Aimmune
Aimmune Therapeutics, Inc. is a biopharmaceutical company
developing and commercializing treatments for potentially
life-threatening food allergies. With a mission to improve the
lives of people with food allergies, Aimmune is developing and
commercializing treatments for potentially life-threatening food
allergies. The Company’s Characterized Oral Desensitization
ImmunoTherapy (CODIT™) approach is intended to provide meaningful
levels of protection against allergic reactions resulting from
accidental exposure to food allergens by desensitizing patients
with defined, precise amounts of key allergens. Aimmune has one
FDA-approved medicine for peanut allergy and other investigational
therapies in development to treat other food allergies. For more
information, please visit www.aimmune.com.
Forward-Looking Statements
Statements contained in this press regarding matters that are
not historical facts are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding: Aimmune’s
expectations regarding the launch of PALFORZIA in the United
States; the potential approval of and launch timing for AR101 in
Europe; and potential applications of the CODIT approach to
treating life-threatening food allergies. Risks and uncertainties
that contribute to the uncertain nature of the forward-looking
statements include: the risk that the COVID-19 worldwide pandemic
may continue to negatively impact the business, research and
clinical operations of Aimmune or its partners; Aimmune’s or any of
its collaborative partners’ ability to initiate and/or complete
clinical trials; the unpredictability of the regulatory process;
the possibility that Aimmune’s or any of its collaborative
partners’ clinical trials will not be successful; Aimmune’s
dependence on the success of PALFORZIA; Aimmune’s reliance on third
parties for the manufacture of Aimmune’s products and product
candidates; possible regulatory developments in the United States
and foreign countries; and Aimmune’s ability to attract and retain
senior management personnel. These and other risks and
uncertainties are described more fully in Aimmune's most recent
filings with the Securities and Exchange Commission, including its
Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Aimmune
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
This press release concerns PALFORZIA, which has been approved
for marketing by the FDA in the United States and has not been
approved for marketing by the EMA or Swissmedic. PALFORZIA in
Europe is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
PALFORZIA®, AIMMUNE®, AIMMUNE THERAPEUTICS® and CODIT™ are
trademarks of Aimmune Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200706005106/en/
Investors: Aimmune Investor Relations (650) 614-5220
ir@aimmune.com
Media: Jodi Sievers (650) 250-6849
Jsievers@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Jul 2023 to Jul 2024